Tonix gets FDA alignment on Lyme disease antibody study design
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced it has received official minutes from a Type C meeting with the U.S ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
